Oncotarget

Research Papers:

The La protein counteracts cisplatininduced cell death by stimulating protein synthesis of antiapoptotic factor Bcl2

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:29664-29676. https://doi.org/10.18632/oncotarget.8819

Metrics: PDF 1902 views  |  Full Text 3210 views

Tilman Heise1, Venkatesh Kota1, Alexander Brock1, Amanda B. Morris1, Reycel M. Rodriguez1, Avery W. Zierk1, Philip H. Howe1, Gunhild Sommer1

1Medical University of South Carolina (MUSC), Department of Biochemistry & Molecular Biology, Charleston, SC 29425, USA

Correspondence to:

Gunhild Sommer, e-mail: [email protected]

Keywords: La/SSB, LARP3, RNA-binding protein, cisplatin, mRNA translation

Received: November 13, 2015    Accepted: March 28, 2016    Published: April 18, 2016

ABSTRACT

Up-regulation of anti-apoptotic factors is a critical mechanism of cancer cell resistance and often counteracts the success of chemotherapeutic treatment. Herein, we identified the cancer-associated RNA-binding protein La as novel factor contributing to cisplatin resistance. Our data demonstrate that depletion of the RNA-binding protein La in head and neck squamous cell carcinoma cells (HNSCC) increases the sensitivity toward cisplatin-induced cell death paralleled by reduced expression of the anti-apoptotic factor Bcl2. Furthermore, it is shown that transient expression of Bcl2 in La-depleted cells protects against cisplatin-induced cell death. By dissecting the underlying mechanism we report herein, that the La protein is required for Bcl2 protein synthesis in cisplatin-treated cells. The RNA chaperone La binds in close proximity to the authentic translation start site and unwinds a secondary structure embedding the authentic AUG. Altogether, our data support a novel model, whereby cancer-associated La protein contributes to cisplatin resistance by stimulating the translation of anti-apoptotic factor Bcl2 in HNSCC cells.